ClinicalTrials.gg
Not yet recruitingNCT07234526Updated Nov 19, 2025

Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients

An observational study in Glucose Fluctuations in Sepsis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Sepsis by Assiut University — 23 open to participants now, 23 under way, 1 of them phase 3. Sepsis · Assiut University.

Planned enrollment
10th of 29
105 · median 100
Started
2026
with 12 others
Observational
29 of 33
20 open now
Primary completion
2028-12
later than 21 of 22 live
Registered
19th of 33
by date

Among the 33 studies in Sepsis by Assiut University, this one is the 10th largest by planned enrollment of the 29 observational ones that give a count, is one of 13 that started in 2026, is one of 29 observational ones, reaches primary completion later than 21 of the 22 other live ones, and was the 19th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

23 of the 33 studies in Sepsis by Assiut University are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Sepsis by Assiut University, or all of them as a file.
02

Study summary

To determine whether glucose fluctuations prior to antibiotic administration are associated with sepsis severity and poor clinical outcomes.

  • To assess if the time to Glycemic Normalization after Antibiotic Initiation can be used as an Early Prognostic Indicator in Sepsis.
  • To evaluate the Glycemic Shock Index (GSI) as a Combined Marker of Hemodynamic and Metabolic Stress in ICU Sepsis Patients.
Read the detailed description

Sepsis is a life-threatening condition caused by the body's overwhelming response to infection. It is a major cause of death in intensive care units (ICUs) despite advances in treatment. One of the body's common responses to sepsis is a disturbance in blood sugar levels, even in patients without diabetes. These changes, known as glycemic variability, include both high and low glucose levels and rapid swings between them.

Recent studies suggest that glycemic variability the early hours of sepsis may be linked to worse outcomes, including organ failure and death .Unlike average glucose levels, these fluctuations can reflect how stressed the body is.

A newer marker called the Glycemic Shock Index (GSI) - calculated by dividing blood glucose by mean arterial pressure (MAP)- may help capture both metabolic and circulatory stress.

Another factor of interest is the time it takes for blood sugar to return to normal after starting antibiotics.

Early normalization may signal a better response to treatment, while persistent abnormal levels could predict complications.

Understanding how early glucose changes relate to sepsis severity may help us identify high-risk patients sooner. This study focuses on glucose fluctuations before antibiotics, time to glucose normalization, and GSI, and how they relate to outcomes like mortality, organ failure like AKI and ICU stay.

03

Conditions studied

  • Glucose Fluctuations in Sepsis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critical care unit of assiut university hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years admitted to ICU with suspected or confirmed sepsis.
  • Sepsis diagnosed using Sepsis-3 criteria (infection + SOFA ≥2).
  • At least 2 blood glucose readings within 6 hours prior to the first dose of antibiotics.
  • at least 3 after starting antibiotics within 24 hours.

Exclusion criteria

Exclusion Criteria:

  • use in prior 48 hours.
  • DKA, HHS, or acute pancreatitis.
  • Incomplete glucose data or delayed documentation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. ICU mortality

    ICU mortality due to septic shock and associated glucose level fluctuations pre and post antibiotic administration

    Time frame: Baseline

  2. AKI

    number of patients suffering from AKI due to septic shock

    Time frame: Baseline

Secondary outcomes

  1. Need for vasopressor support within first 24 hours.

    Number of patients who needed norepinephrine or other vasopressors during first day of ICU admission

    Time frame: First 24 hours of ICU admission

  2. Length of ICU stay

    Length of ICU stay until improvement or death

    Time frame: Start from patient admission to ICU unti patient discharge or death for any cause (whichever comes first) up to 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Patients may not agree

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Nov 18, 2025
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Jun 1, 2029
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07234526
Lead sponsor
Assiut University
Responsible party
Shaban Nady Sedky Tamer (Resident physician, Assiut University) — Principal investigator
First posted
Nov 18, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 19, 2025

Study contacts

Shaban N S Tamer, Bachelor degree of medicin
Contact
shabaan2021@icloud.com
+201286606934
Dina A Ahmed, Doctorate of internal medicine
Contact
dinaalihamad@aun.edu.eg
+20106 3040703
Muhammad Abbas Al masry, Doctorate of internal medicine
study director

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion